Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients

Diabetologia

Volumn 39, Issue 6, 1996, Pages 701-709

  Kumar, S ^a   Boulton, A J M ^a   Beck Nielsen, H ^b   Berthezene, F ^c   Muggeo, M ^d   Persson, B ^e   Spinas, G A ^f   Donoghue, S ^g   Lettis, S ^g   Stewart Long, P ^g  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Hopital de l'Antiquaille   (France)

^d UNIVERSITY OF VERONA   (Italy)

^e Sahlgren Institute   (Sweden)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Insulin resistance; Non insulin dependent diabetes mellitus; Oral anti diabetic agent; Thiazolidinedione; Troglitazone

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG THERAPY; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CHOLESTEROL; CHROMANS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LEUKOCYTE COUNT; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NEUTROPHILS; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0029999139     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00418542     Document Type: Article

References (33)

1. De Fronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368
2. Turner RC, Matthews DR, Holman RR, Peto J (1982) Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes. Lancet 1:596-598
3. Yki-Jarvinen H (1994) Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343: 91-95
4. WHO Study Group (1994) Prevention of diabetes mellitus, WHO Technical Report Series 844. World Health Organisation, Geneva, pp 3-7
5. Martin BC, Warram JH, Krowlewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25 year follow-up study. Lancet 340: 925-929
6. DeFronzo RA, Ferrannini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194
7. Eriksson KF, Lindgärde F (1991) Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 34:891-898
8. Page RCL, Harnden KE, Cook JTE, Turner RC (1992) Can life-styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabet Med 9: 562-566
9. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterisation of a new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558
10. Hargrove DM, Kreutter DK, Gibbs EM, Stevenson RW (1990) Mechanism of action of thiazolidinedione antidiabetic agents. In: Shaffir E (ed) Frontiers in diabetes research, Vol 3, 1st edn. Smith-Gordon, New York, pp 313-319
11. Kellerer M, Kroder G, Tippmer S et al. (1994) Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 43: 447-453
12. Kuzuya T, Iwamoto Y, Kosaka K et al. (1991) A pilot clinical trial of a new oral hypoglycaemic agent CS-045 in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11: 147-154
13. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JY (1992) Metabolic effects of a new oral hypoglycaemic agent, CS-045 in NIDDM subjects. Diabetes Care 15: 193-203
14. Mimura K, Umeda F, Hiramatsu S et al. (1994) Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11: 685-691
15. Schnek AG, Schroeder WA (1961) The relationship between the minor components of whole normal adult haemoglobin as isolated by chromatography and starch block electrophoresis. J Am Chem Soc 83: 1472-1476
16. Soeldner JS, Slone D (1965) Critical variables in the radioimmunoassay of serum insulin using the double antibody technique. Diabetes 14: 771-779
17. Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541-548
18. Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of concentrations of low density lipoprotein cholesterol in plasma, without the use of ultracentrifugation. Clin Chem 18: 499-502
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419
20. Fleiss JL (1986) The design and analysis of clinical experiments. Wiley, New York, pp 186-207
21. Williams G (1994) Management of non-insulin-dependent diabetes mellitus. Lancet 343: 95-100
22. Gerich JE (1989) Oral hypoglycaemic agents. N Engl J Med 321: 1231-1245
23. Kosaka K, Kuzuya T, Akanuma Y, Hagura R (1980) Increase in insulin response after treatment of overt maturity-onset diabetes is independent of mode of treatment. Diabetologia 18: 23-28
24. Randle PJ, Kerbey A, Espinal J (1988) Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metabol Rev 4: 623-638
25. Reaven GM (1995) The fourth musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 38: 3-13
26. Lehman JM, Moore LB, Smith-Oliver TA et al. (1995) An antidiabetic thiazolidine dione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270(22):12953-12956
27. Kumar S, Durrington PN, Bhatnagar D, Laing I (1994) Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome. Lancet 343: 1073-1074
28. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193
29. Yoshioka T, Aizawa Y, Fujita T et al. (1991) Studies on hindered phenols and analogues. V. Synthesis, identification and anti-diabetic activity of the glucoronide of CS-045. Chem Pharma Bull 39: 2124-2125
30. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K (1995) Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8:316-320
31. Hermann LS, Schersten B, Bitzen P et al. (1994) Therapeutic comparison of metformin and sulphonylurea, alone and in various combinations. Diabetes Care 17: 1100-1109
32. Hoffmann J, Spengler M (1994) Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 17: 561-566
33. UK Prospective Diabetes Study Group (1995) United Kingdom Prospective Diabetes Study Group (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310: 83-88